These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 2826175)
1. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action. Czlonkowski A; Millan MJ; Herz A Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175 [No Abstract] [Full Text] [Related]
2. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine. Takahashi M; Senda T; Kaneto H Eur J Pharmacol; 1991 Aug; 200(2-3):293-7. PubMed ID: 1664330 [TBL] [Abstract][Full Text] [Related]
3. Attenuation of the antinociceptive action of the selective kappa-opioid receptor agonist, U-50,488H by ICS-205-930. Ho BY; Takemori AE Eur J Pharmacol; 1990 Mar; 178(3):371-3. PubMed ID: 2160372 [TBL] [Abstract][Full Text] [Related]
4. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats. Fukagawa Y; Katz JL; Suzuki T Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895 [TBL] [Abstract][Full Text] [Related]
5. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats. Yamamoto T; Ohno M; Ueki S Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208 [TBL] [Abstract][Full Text] [Related]
6. Contribution of supraspinal mu- and delta-opioid receptors to antinociception in the rat. Miaskowski C; Taiwo YO; Levine JD Eur J Pharmacol; 1991 Dec; 205(3):247-52. PubMed ID: 1667910 [TBL] [Abstract][Full Text] [Related]
7. Selective kappa opioid agonist for spinal analgesia without the risk of respiratory depression. Castillo R; Kissin I; Bradley EL Anesth Analg; 1986 Apr; 65(4):350-4. PubMed ID: 3006552 [TBL] [Abstract][Full Text] [Related]
8. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists. Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265 [TBL] [Abstract][Full Text] [Related]
9. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883 [TBL] [Abstract][Full Text] [Related]
10. Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats. Diop L; Rivière PJ; Pascaud X; Dassaud M; Junien JL Eur J Pharmacol; 1994 May; 257(1-2):181-7. PubMed ID: 8082700 [TBL] [Abstract][Full Text] [Related]
11. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. Millan MJ; Członkowski A; Lipkowski A; Herz A J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723 [TBL] [Abstract][Full Text] [Related]
12. Tonic pain perception in the mouse: differential modulation by three receptor-selective opioid agonists. Murray CW; Cowan A J Pharmacol Exp Ther; 1991 Apr; 257(1):335-41. PubMed ID: 1850470 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions. Ohno M; Yamamoto T; Ueki S Psychopharmacology (Berl); 1989; 97(2):219-21. PubMed ID: 2543013 [TBL] [Abstract][Full Text] [Related]
14. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist. Bhargava HN; Ramarao P; Gulati A Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058 [TBL] [Abstract][Full Text] [Related]
15. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats. Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade. Pugsley MK; Penz WP; Walker MJ; Wong TM Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979 [TBL] [Abstract][Full Text] [Related]
17. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord. Bhargava HN; Gulati A; Ramarao P J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075 [TBL] [Abstract][Full Text] [Related]
18. Antinociception produced by receptor selective opioids: modulation of spinal antinociceptive effects by supraspinal opioids. Miaskowski C; Levine JD Brain Res; 1992 Nov; 595(1):32-8. PubMed ID: 1334770 [TBL] [Abstract][Full Text] [Related]
19. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat. Bhargava HN; Gulati A; Rahmani NH Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157 [TBL] [Abstract][Full Text] [Related]
20. A kappa opiate agonist, U50,488H, enhances energy expenditure in rats. Mandenoff A; Seyrig JA; Betoulle D; Brigant L; Melchior JC; Apfelbaum M Pharmacol Biochem Behav; 1991 May; 39(1):215-7. PubMed ID: 1656474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]